Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking … Read more
Q32 Bio Inc (QTTB) - Net Assets
Latest net assets as of September 2025: $-18.45 Million USD
Based on the latest financial reports, Q32 Bio Inc (QTTB) has net assets worth $-18.45 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.78 Million) and total liabilities ($76.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-18.45 Million |
| % of Total Assets | -31.93% |
| Annual Growth Rate | -3.43% |
| 5-Year Change | -97.1% |
| 10-Year Change | N/A |
| Growth Volatility | 464.95 |
Q32 Bio Inc - Net Assets Trend (2016–2024)
This chart illustrates how Q32 Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Q32 Bio Inc (2016–2024)
The table below shows the annual net assets of Q32 Bio Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.67 Million | +103.10% |
| 2023-12-31 | $-182.92 Million | -39.94% |
| 2022-12-31 | $-130.71 Million | -177.05% |
| 2021-12-31 | $169.65 Million | -13.44% |
| 2020-12-31 | $196.00 Million | -24.18% |
| 2019-12-31 | $258.51 Million | +31.65% |
| 2018-12-31 | $196.35 Million | +99.73% |
| 2017-12-31 | $98.31 Million | +1210.72% |
| 2016-12-31 | $7.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Q32 Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22462399700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.04% |
| Other Components | $240.49 Million | 4237.66% |
| Total Equity | $5.67 Million | 100.00% |
Q32 Bio Inc Competitors by Market Cap
The table below lists competitors of Q32 Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
$33.90 Million |
|
Novacyt S.A
PINK:NVYTF
|
$33.90 Million |
|
CIG PANNONIA LIFE INSURA.
F:0CKA
|
$33.90 Million |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
$33.91 Million |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
$33.88 Million |
|
Hantech Bio-Technology Co., Ltd.
TWO:1294
|
$33.88 Million |
|
HeXun Biosciences Co., Ltd.
TWO:6986
|
$33.87 Million |
|
Articore Group Ltd
AU:ATG
|
$33.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Q32 Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -182,921,000 to 5,675,000, a change of 188,596,000.
- Net loss of 47,733,000 reduced equity.
- New share issuances of 42,000,000 increased equity.
- Other comprehensive income increased equity by 5,000.
- Other factors increased equity by 194,324,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.73 Million | -841.11% |
| Share Issuances | $42.00 Million | +740.09% |
| Other Comprehensive Income | $5.00K | +0.09% |
| Other Changes | $194.32 Million | +3424.21% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Q32 Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.70x to 13.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $3.61 | $6.13 | x |
| 2017-12-31 | $47.28 | $6.13 | x |
| 2018-12-31 | $123.79 | $6.13 | x |
| 2019-12-31 | $110.48 | $6.13 | x |
| 2020-12-31 | $76.84 | $6.13 | x |
| 2021-12-31 | $55.24 | $6.13 | x |
| 2022-12-31 | $-40.99 | $6.13 | x |
| 2023-12-31 | $-56.83 | $6.13 | x |
| 2024-12-31 | $0.47 | $6.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Q32 Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -841.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 16.27x
- Recent ROE (-841.11%) is below the historical average (-129.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -107.29% | 0.00% | 0.00x | 1.90x | $-8.80 Million |
| 2017 | -30.51% | 0.00% | 0.00x | 1.40x | $-39.82 Million |
| 2018 | -28.30% | -1044.29% | 0.02x | 1.32x | $-75.21 Million |
| 2019 | -40.20% | -6237.45% | 0.01x | 1.20x | $-129.77 Million |
| 2020 | -65.66% | -4762.92% | 0.01x | 1.35x | $-148.29 Million |
| 2021 | -56.45% | -281.90% | 0.16x | 1.25x | $-112.73 Million |
| 2022 | 0.00% | -643.65% | 0.11x | 0.00x | $-29.74 Million |
| 2023 | 0.00% | 0.00% | -0.14x | 0.00x | $-35.45 Million |
| 2024 | -841.11% | 0.00% | 0.00x | 16.27x | $-48.30 Million |
Industry Comparison
This section compares Q32 Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Q32 Bio Inc (QTTB) | $-18.45 Million | -107.29% | N/A | $33.88 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |